STAT

Opinion: Is there a conflict of interest behind your cancer diagnosis?

Relatively few people explore their pathologist's financial conflicts of interest. More should do that: 1 in 4 pathologists gets payments from industry.

My mother was astonished when I told her about the national Open Payments database that was launched by the Affordable Care Act. “You mean I can see all the money drug companies have given to a doctor? Even my doctor?” We plugged her doctor’s name into the database and up it popped, associated with a number of payments. He had recently prescribed an expensive, brand-name drug for my mother; she had questioned whether a cheaper, older alternative might be just as good. It turned out that her doctor had received payments from the company producing that brand-name drug.

I don’t know, of course, if her doctor’s recommendation had been influenced by these payments or if his choice

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.

Related Books & Audiobooks